Skip to main content

Table 4 Proportion of patients with sufficient overall symptom relief after 4 weeks of treatment with omeprazole, famotidine, mosapride or teprenone, grouped by symptom severity, number of symptoms and symptom type

From: Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)

  

Omeprazole

Famotidine

Mosapride

Teprenone

  

n

Proportion with sufficient overall symptom relief

n

Proportion with sufficient overall symptom relief

n

Proportion with sufficient overall symptom relief

n

Proportion with sufficient overall symptom relief

Symptom severity *

Moderate

104

72.1%

96

44.8%

91

38.5%

47

29.8%

Severe

29

48.3%

26

26.9%

22

27.3%

18

38.9%

Number of symptoms

≤ 4

28

78.6%

36

55.6%

23

43.5%

14

64.3%

≥ 5

105

63.8%

86

34.9%

90

34.4%

51

23.5%

Predominant symptom type †

GERD

56

76.8%

36

22.2%

35

45.7%

21

23.8%

Dyspepsia

95

68.4%

93

47.3%

77

40.3%

51

33.3%

Other

59

62.7%

46

34.8%

55

30.9%

30

26.7%

  1. *Moderate was defined as a GOS of 4 or 5, and severe as a GOS of 6 or 7.
  2. †Symptoms were categorized as ‘GERD’ if the symptom with the highest score was heartburn or regurgitation, as ‘dyspepsia’, if the symptom with the highest score was epigastric pain or early satiety, and as ‘other’ if the symptom with the highest score was nausea/vomiting, belching or bloating. A joint highest score for more than one symptom type was possible. GERD, gastroesophageal reflux disease; GOS, Global Overall Symptom score.